<DOC>
	<DOCNO>NCT01969799</DOCNO>
	<brief_summary>To demonstrate safety efficacy adjunctive therapy Amikacin fosfomycin inhalation system ( AFIS ) versus aerosolize placebo treat Gram-negative pneumonia mechanically ventilate patient receive IV antibiotic .</brief_summary>
	<brief_title>Aerosolized Amikacin Fosfomycin Mechanically Ventilated Patients With Gram-negative Pneumonia</brief_title>
	<detailed_description>The primary purpose study demonstrate safety efficacy amikacin fosfomycin inhalation system ( AFIS ) . AFIS consist amikacin solution fosfomycin solution , deliver aerosol lung via PARI Investigational eFlow Inline System ( eFlow Inline System ) . All patient receive standardized course intravenous ( IV ) antibiotic minimum 7 day . Patients randomize receive 10 day treatment either AFIS placebo , addition IV therapy . The primary efficacy endpoint define change baseline Clinical Pulmonary Infection Score ( CPIS ) randomize course study drug .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Males nonpregnant , nonlactating female , ≥ 18 year ≤ 80 year age Intubated mechanically ventilated Diagnosis pneumonia , define presence new progressive infiltrate ( ) recent chest radiograph prior screening , determine treat physician Signs infection ( within 24 hour prior screen ) : 1 . Fever ( &gt; 38ºC &gt; 100.4ºF ) ; 2 . Leukopenia ( &lt; 4,000 WBC/mm3 ) leukocytosis ( ≥ 12,000 WBC/mm3 ) Impaired oxygenation ( within 24 hour prior screen ) : a. PaO2/FiO2 ≤ 350 mmHg Acute Physiology Chronic Health Evaluation ( APACHE ) II score &gt; 10 ( within 24 hour prior screen ) Presence , high suspicion , Gramnegative organism ( ) either Gram stain culture respiratory secretion sample obtain within previous 7 day ( enrollment occur culture result available ) History hypersensitivity amikacin , aminoglycosides , fosfomycin , imipenem , meropenem , colistin Received systemic antibiotic therapy episode Gramnegative pneumonia great 72 hour time randomization PaO2/FiO2 ≤ 100 mmHg diffuse infiltrate Chest Xray Refractory septic shock ( severe sepsis plus unstable hypotension , spite adequate fluid resuscitation vasopressor ) Any follow condition interfere assessment interpretation diagnosis response therapy : 1. chest trauma ongoing loss stability thoracic cage follow fracture sternum , rib , ; 2. increase amount fluid lung cavity require chest tube drainage ; 3. lung cancer within last 2 year ; 4. lung abscess ( ) ; 5. anatomical bronchial obstruction ; 6. suspect atypical pneumonia ; 7. chemical pneumonitis ( e.g. , inhalation injury ) ; 8. cystic fibrosis Immunocompromised patient , include neutropenia NOT due current infection ( absolute neutrophil count &lt; 500/mm3 ) , leukemia , lymphoma , human immunodeficiency virus ( HIV ) infection CD4 count &lt; 200 cells/mm3 , splenectomy ; early posttransplantation ( &lt; 3 month posttransplant , &gt; 3 month posttransplant evidence organ rejection clinical criterion , pathologic confirmation , modification immunosuppression within past 4 week ) , cytotoxic chemotherapy , highdose steroid ( e.g. , &gt; 40 mg prednisone equivalent [ &gt; 160 mg hydrocortisone , &gt; 32 mg methylprednisolone , &gt; 6 mg dexamethasone , &gt; 200 mg cortisone ] daily &gt; 2 week ) Evidence significant renal impairment ( serum creatinine &gt; 4.0 mg/dL within 24 hour prior screen ) . If serum creatinine &gt; 2.0 mg/dL , site must capable perform continuous renal replacement therapy , clinically indicate . Patients serum creatinine &gt; 4.0 mg/dL treat continuous renal replacement therapy ( continuous venousvenous hemofiltration continuous venousvenous hemodialysis ) chronic hemodialysis eligible Evidence ototoxicity ( history hearing aid use prior current hospitalization ) Evidence hepatotoxicity ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] &gt; 3X upper limit normal value within 24 hour prior screen ) Positive urine and/or serum betahCG pregnancy test ( woman reproductive age ) On mechanical ventilation &gt; 28 day Glasgow Coma Scale score =3 Screening Participating participated investigational interventional study ( drug device ) within last 30 day ( 5 time halflife previously administer investigational compound , whichever long ) prior study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gram-negative pneumonia</keyword>
	<keyword>Aerosol antibiotic</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Fosfomycin</keyword>
	<keyword>Pneumonia , Bacterial</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>